##about.aboutContext##
Open Access Policy
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Aims and Scope
The Research in Molecular Medicine (RMM) is devoted to the rapid publication of fundamental and applied research articles on all aspect of molecular medicine. RMM will bring together work focusing on common pathogenic processes, and provide a forum for integrative reviews and commentaries on this field. RMM will cover studies related to clinical and experimental original papers, review articles and correspondence of the highest quality pertinent to all aspects of human biology and pathophysiology.
RMM committed to providing an efficient service for both authors and readers, and exists to facilitate the rapid peer review and publication of research. With the support of an internal and external Editorial Boards and a streamlined peer-review system, all papers are rapidly and fairly peer reviewed to ensure they are technically sound.
Abstracting and Indexing
The following is a list of the Indexing databases that cover Research in Molecular Medicine hosted by Knowledge E.
|
Chemical abstract (CAB) |
Indexed |
|
|
DOAJ |
Indexed |
|
|
IMEMR-WHO |
Indexed |
|
|
ISC |
Indexed |
|
|
Iran Medex |
Indexed |
|
|
SID |
Indexed |
|
|
Magiran |
Indexed |
|
|
HANARI |
Indexed |
|
|
SFU |
Indexed |
|
|
Geneva |
Indexed |
|
|
Journal TOCs |
Indexed |
|
|
Electronic Journal Library |
Indexed |
|
|
ICMJE |
Indexed |
|
|
PubsHub |
Indexed |
|
|
Proquest |
Indexed |
Author Guidelines
Research in Molecular Medicine (RMM) which will be an international peer-reviewed journal, which aims to publish high quality basic and clinical research in the fields of molecular medicine.
In this Journal, we will focus on the research in molecular aspects of diseases such as cancer, autoimmune disorders, allergic diseases, genetic diseases, infectious diseases, and psychiatry disorders. RMM will be welcome to receive manuscripts throughout the world. For this matter, manuscripts from authors anywhere worldwide will be considered for publication. We are committed to maintain high scientific standards and a broad international coverage ensured by internal and external editorial boards with extensive academic qualifications.
RMM welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence in this subject area, and will publish:
• Original articles in basic and clinical research
• Brief articles
• Case studies
• Critical reviews, systematic review, opinions, commentaries
• Letter to the editor.
According to your expertise, unparalleled curricula and vast knowledge in the fields of research in molecular medicine we will welcome your manuscripts relating RMM aims, to submit through the RMM website: http://rmm.mazums.ac.ir.
If you experience any problem, please contact our editorial office by e-mail at: [email protected] or [email protected]
Submission of manuscripts
Manuscripts should be typed in 1.5 line spacing and 12 pt. Time New Roman with ample margins. Number all pages consecutively, and start each of the following sections on a new page:
- Cover letter
- Title & Running Title
- Abstract
- Introduction
- Materials and Methods
- Statistics
- Results
- Discussion
- Acknowledgments
- Conflicts of Interest
- References
- Tables
- Figures
- Figure Legends
All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Time New Roman with ample margins. Required information for each of the manuscript sections is as follows: Title page The title page should carry.
Cover Letter
A cover letter should be written like a standard business letter. Address the editor formally by name, if known. Include your contact information, as well. This information is probably available through the journal’s online submission system, but it is proper to provide it in the cover letter, too. every cover letter should contain the following elements:
1. An introduction stating the title of the manuscript and the journal to which you are submitting.
2. The reason why your study is important and relevant to the journal’s readership or field.
3. The question your research answers.
4. Your major experimental results and overall findings.
5. The most important conclusions that can be drawn from your research.
6. A statement that the manuscript has not been published and is not under consideration for publication in any other journal
7. A statement that all authors approved the manuscript and its submission to the journal.
8. Any other details that will encourage the editor to send your manuscript for review.
Write one or more sentences to address each of these points. You will revise and polish these sentences to complete your cover letter.
Title Page
The title page must contain the following information:
• Type of manuscript (e.g. Original article, Review article, Case Report, …)
• Title: Title should be less than 12 words.
• Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors.
• Running title: A short running title of less than 6 words (less than 50 characters) should be provided.
• Affiliation/ Institution: Author names should be given first, then the complete name of institution, city, province and postcode.
• Correspondence to: Only one corresponding address should be affiliation, the complete name of institution, city, postcode, province, country, telephone, fax, and email. All the letters in the email should be in lower case. Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Tel/fax: + 98-11-33543614.
• Up to five keywords or phrases suitable for use in an index (it is recommended to use MeSH terms).
• Word count, excluding title page, abstract, references, figures and tables.
• Registration number of clinical trials
Abstract
Abstract should be structured with no more than 400 words for original articles and 250 words for brief articles and review articles. The specific requirements for abstracts are as follows:
BACKGROUND : (no more than 40 words), AIM (no more than 25 words), only the purpose should be included.
MATERIALS AND METHODS: (no more than 130 words)
RESULTS : (no more than 170 words), you should present P values where appropriate and must provide relevant data to illustrate how they were obtained;
CONCLUSION : (no more than 35 words), the abstract should not be structured for other types of articles. Do not include references in abstract.
KEYWORDS: Please list 3-7 key words, selected mainly from Index Medicus, which reflect the content of the study. Key word should be arranged alphabetically.
Text
For articles of these sections, original articles, brief articles and case reports, the main text should be structured into the following sections:
INTRODUCTION ; State the purpose and summarize the rationale for the study or observation.
MATERIALS AND METHODS ; this section should only include information that was available at the time the study was planned or protocol written; all information obtained during the conduct of the study belongs to the results section. Selection and Description of Participants: Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. Because the relevance of such variables as age and sex to the object of research is not always clear, authors should explain their use when they are included in a study report; for example, authors should explain why only subjects of certain ages were included or why they excluded a gender from the study. The guiding principle should have clarity about how and why a study was done in a particular way. When authors use variables such as race or ethnicity, they should define how they measured the variables and justify their relevance. Technical information: Identify the methods, apparatus (give the manufacturer's name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods; provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement ( http://www.consort-statement.org ).
Statistics
Statistics; whenever possible quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Define the statistical methods used to analyze the variables. Report losses to observation (such as drop outs from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyze them. Define statistical terms, abbreviations, and most symbols. Specify the computer software used. For all P values include the exact value and not less than 0.05 or 0.001.
Results
Result; Present your results in a logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Data should be presented in the main text or in Figures and Tables, but not in both. On the other hand, do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations. Extra or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal. When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical methods used to analyze them. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. "Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
Discussion
Include summary of key findings; Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research). Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, contributors should avoid making statements on economic benefits and costs unless their manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. State new hypotheses when warranted, but clearly label them as such.
Acknowledgements
Acknowledgements Brief acknowledgements of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.
Conflicts of Interest
All authors of submitting articles to the journal must disclose any conflict of interest they may have with an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript. The Editor will discuss with the authors on an individual basis the method by which any conflicts of interest will be communicated to the readers.All authors must submit a statement of conflict of Interest to be published at the end of their article (conflict of Interest: non declared).
References
This Journal accepts references according to a style based on Vancouver style (with some minor changes). Vancouver, a numbered style, follows rules established by the International Committee of Medical Journal Editors. Writing references as an ENDNOTE file will be considered as an advantage when submitting a manuscript. IN the text references: References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). If the same source is cited again later in the text, the same number is used once more. If multiple references are cited, use a hyphen to join an inclusive range of numbers thus: 2-5. Use commas without spaces to separate non-inclusive numbers in a multiple citation thus: 2-5,7,10. Identify references in text, tables, and legends by Arabic numerals in superscript with after the punctuation marks. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. Use the style of the examples below, which are based on the formats used by the NLM in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus. Use complete name of the journal for non-indexed journals. Avoid using abstracts as references. Information from manuscripts submitted but not accepted should be cited in the text as "unpublished observations" with written permission from the source. Avoid citing a "personal communication" unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author’s name. Do not list the same citation twice. The commonly cited types of references are shown here, for other types of references such as electronic media; newspaper items, etc. please refer to ICMJE Guidelines (http://www.icmje.org or http://www.nlm.nih.gov/bsd/uniform_requirements.html ).
Figures /illustrations
Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. It is our principle to publish high resolution figures for the printed and E-versions. If digital images are the only source of images, ensure that the image has minimum resolution of 300 dpi or 1800 x 1600 pixels in TIFF format. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas.
Tables
Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.
Online Submission of the Manuscripts
All manuscripts must be submitted on-line through the website http://rmm.mazums.ac.ir. First time users will have to register at this site. Registered authors can keep track of their articles after logging into the site using their user name and password. Submission, processing or publication of articles in the RMM is free of charge. If you experience any problems, please contact our editorial office by e-mail at [email protected] or [email protected].
Full papers should follow the basic structure of abstract, introduction, methods, results, discussion, references, and tables and figures as appropriate.
Categories of manuscripts
|
S. No |
Manuscripts |
Word limit of abstract |
Word limit of manuscript |
Comments |
|
1 |
Editorial |
NA |
1200 |
Usually Invited |
|
2 |
Original Article |
250- 400 |
3000 |
Structured abstract |
|
3 |
Review |
200–250 |
4000 |
Abstract should be unstructured but for systematic review it should be structured |
|
4 |
Short Communication |
200 - 250 |
2000 |
Structured abstract |
|
5 |
Letter to the Editor |
NA |
500 |
|
|
6 |
Fillers (ADR Reports, Ethics, Drug Reviews, Journal Club, News, Conference Report etc. ) |
NA |
No fixed word limit |
Copyright Form
All authors should fulfill their complete names and sign the copyright form which is available in word format. Author should print, sign, scan and send this form by email to [email protected] or [email protected] The copyright form is available to download by clicking on Download Copyright Form , Consent form
Article submission steps:
• Registration as a user in website
• Receiving the article special code
• Filling the article form with required data
• Checking the article and submitting related files and comments in the private page
• Approving the article
Plagiarism detection
Any practice of plagiarism will not be tolerated regarding submitted articles. Non-identifiable quoted parts of the articles from other authors are known act of plagiarism if it is not cited or referencing in appropriate places in the article. Advertent practice of plagiarism will abort reviewing process or article submission.
Editorial Board
Andreas Lunpqvist, PhD
Department of Oncology and Pathology, Cancer Centre Karolinska (R8:01), Karolinska Institute, Stockholm, Sweden
[email protected]
Said Abedian, PhD
Department of Immunology, Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Hamid mohammad Jafari, MD
Department of Pediatrics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Abolghsem Ajami, PhD
Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Reza Jafari shakib, PhD
Department of Immunology and Microbiology, Rasht Medical School, Gilan University of Medical Sciences, Rasht, Iran
[email protected]
Hossein Asgarian, PhD
Department of Immunology, School of Medicine, Mazandaran University
of Medical Sciences, Sari, Iran
[email protected]
Ghasem Jan Babaei, MD
Department of Internal Medicine, , Faculty of Medicine,Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Hamid Badali, PhD
Department of Medical Mycology & Parasitology/Invasive Fungi Research Center (IFRC), Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Alireza khalatbari, PhD
Department of Anatomy, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Arunaloke Chakrabarti, MD
Mycology Division, Department of Medical Microbiology, PGIMER, Chandigarh, India
[email protected]
Rami Mahfouz, MD
IFCAP, Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon
[email protected]
Ahmad Daryani, PhD
Toxoplasmosis Research Center, Mazandaran University of Medical
Science, Sari, Iran
[email protected]
Jacques F. Meis, MD-PhD
Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
[email protected]
Ahmadali Enayati, PhD
Department of Entomology, Health Sciences Research Center Faculty of Health's, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
D. Scott Merrell, PhD
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA
[email protected]
Mehdi Fakhar, PhD
Department of Parasitology, Molecular and Cell
Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Seppo Meri, MD-PhD
mmunobiology Program, Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland
[email protected]
Ingrid Muller, PhD
Faculty of Medicine, Department of Immunology, Imperial College London, United Kingdom
[email protected]
Ali ghaemian, MD
Department of Cardiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Parviz Owlia PhD
Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
[email protected]
Abass Ghaderi, PhD
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
[email protected]
Alireza Rafiei, PhD
Molecular and Cell Biology Research Center, Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Javad Ghafari, MD
Department of Pediatrics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Hossein Ashrafi, PhD
Institute of Comparative Medicine, Department of Pathological Sciences, Glasgow University, Glasgow, Scotland, United Kingdom
[email protected]
Tim F. Greten, MD-PhD
National Institutes of Health, National Cancer Institute, Medical Oncology Branch, USA
[email protected]
Mohammad Sadegh Rezaei, MD
Department of Pediatrics, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Mohammad reza HaghShenas, PhD,
Department of Microbiology, Faculty of Medicine, Mazandaran University
of Medical Sciences, Sari, Iran
[email protected]
Mehdi Sharif, PhD
Department of Parasitology, Toxoplasmosis Research Center, Faculty of Medical Mycology and Parasitology, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Mehran Haidari, PhD
Molecular cardioloy, Texas Heart Institute, Univ of Texas Health Science Cntr at Houston, Houston, TX
[email protected]
Mohammad Reza Shiran, PhD
Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Mehrdad Hajlooi, PhD
Department of Immunology, Faculty of Medicine, Hamedan University of Medical Sciences and Health Services, Hamedan, Iran
[email protected]
Tahereh Shokuhi, PhD
Department of Medical Mycology, Invasive Fungal Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Mohammad bagher Hashemi-Soteh, PhD
Department of Immunology, Molecular and Cell Biology Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Mohsen Tehrani, MD-PhD
Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
[email protected]
Morteza Hashemzadeh, PhD
Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
[email protected]
Nosratollah Zarghami, PhD
Department of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz 51664, Iran
[email protected]
G. Sybren de Hoog, PhD
Centraalbureau voor Schimmelcultures KNAW Fungal Biodiversity Centre, Utrecht, The Netherland
[email protected]
Alison M kesson, MD-PhD
Infectious Diseases and Microbiology, The Children’s Hospital at Westmead and Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney NSW Australia, Sydney,Australia
[email protected]
Hossein Ghalenoei, PhD
Immuogenetic research center Mazandaran University of Medical Science, Sari, Iran
[email protected]
Aboulghasem Ajami, PhD
Professor, Department of Immunology,
Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran .
[email protected]
Hamid Badali, PhD
Associate Professor, Department of Molecular and Medical Mycology, Faculty of Medicine Mazandaran
University of Medical Sciences, Sari, Iran.
[email protected]
Hamidreza Goli, PhD
Department of Microbiology,
Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
[email protected]
Editorial Process
Publication Ethics
For a peer-reviewed journal, the publication of articles plays an essential role in the development of a coherent network of knowledge. It is, therefore, essential that all publishers, editors, authors, and reviewers, in the process of publishing the journals, conduct themselves in accordance with the highest level of professional ethics and standards.
Authorship
- Acknowledging contributors: All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance or a department chair who provided only general support. Financial and material support should also be acknowledged. Please ensure that anyone acknowledged has granted permission to be listed.
- Contributorship statement: A contributor ship statement is required for every manuscript submitted and should outline who has contributed what to the planning, conduct, and reporting of the work described in the article. This should include both authors and contributors.
- Alteration to authorship: Any change in authors after initial submission must be approved by all authors. This applies to additions, deletions, a change of order to the authors’ names or a change to the attribution of contributions. Any alterations must be explained to the Editor. The Editor may contact any of the authors and/or contributors to ascertain whether they have agreed to any alteration.
The author has the following responsibilities:
- Choose a journal that is appropriate.
- All manuscripts should be written in good English. Read and follow the ‘Instructions for Authors’ carefully and prepare manuscripts according to the format given in Guidelines.
- Keep the editor and publisher informed of any change in contact details.
- Respond to the editor and publisher promptly (including returning the copyright agreement and proofs when asked to do so).
- Declare any conflicts of interest.
- Do not submit the same or similar articles to any other journal.
- Submit original work and avoid fragmenting your research to maximize the number of articles submitted.
- Present an accurate account of the research you have performed and give Sufficient details and references to public sources of information to permit your peers to repeat the work.
- Give credit to other people who have helped or influenced your work.
- Obtain permission to reproduce figures, tables or extensive extracts from the text of a source that is copyrighted or owned by someone else.
- Declare sources of research funding, including any grant ID numbers.
- Make sure that co-authors review the manuscript before you submit it and that all authors agree on the order in which authors will be listed.
- Do not list people as co-authors unless they have made a significant contribution to the work and will share responsibility and accountability for the results.
- Do not make significant changes to your manuscript after it has been accepted without informing the journal editor. Significant changes would include new data, new content or a change in the list of authors. Make sure that you notify the journal if an error is found after publication that would require a correction to be printed.
The reviewer has the following responsibilities:
- Our peer review process is confidential and identities of reviewers cannot be revealed.
- All publication decisions are made by the journal's Editors-in-Chief on the basis of the referees' reports.
- Manuscripts with contents outside the scope will not be considered for review.
- The reviewer should not use for his or her own research any part of any data or work reported in submitted and as yet unpublished articles.
- The reviewer should treat the manuscript in a confidential manner. The manuscript should not be disclosed to or discussed with others except as authorized by the editor.
The editor has the following responsibilities:
-The editor should acknowledge receipt of submitted manuscripts within two working days of receipt and ensure an efficient, fair, and timely review process.
- Manuscripts submitted are first screened by the editors; only those on subject matters within the scope of the Journal are sent to expert referees for evaluation. This two-tier screening process helps to ensure an appropriate focus as well as high scientific quality of the Journal.
- The editor should ensure that submitted manuscripts are processed in a confidential manner, and that no content of the manuscripts will be disclosed to anyone other than the corresponding author, reviewers, and the publisher, as appropriate.
- The editor should not disclose the names and other details of the reviewers to a third party without the permission of the reviewers.
Publishing ethics issues
- Avoid plagiarism: Paraphrasing is rewriting other people’s ideas in different words and referencing them. This is better than quoting because too many quotations will lead to a poorly written assignment. To use an author’s exact words, quote (cite) the author by using quotation marks and referencing the quotation. This would be either in the text or in a footnote at the bottom of the page.
- COPE principle: If any duplication, fabrication, plagiarism and other misconduct is identified, COPE guideline will be followed. The RMM uses the COPE flowchart. All changes in authorships should be done according to COPE principles.
Clinical trial registration
Neither the editors nor the publisher are responsible for the opinions expressed by contributors. We reserve the right to copy-edit accepted manuscripts and put them onto our website. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The register now available is http://www.clinicaltrials.govsponsored by the United States National Library of Medicine, we encourage all potential contributors to register with it. However, in the event that other registers become available, such as http://www.irct.ir, you will be duly notified. A letter of recommendation from each author’s organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected. It is solely recommended that the authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the corresponding author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing. Online submissions Manuscripts should be submitted through the Online Submission System at:http://rmm.mazums.ac.ir. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [email protected], [email protected], or by telephone: +98-11-33543614. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.
Complaints procedure
Complaints may be made by phone, email, or letter. Informing us in writing by email is advised as it provides the most reliable audit trail. Complaints should ideally be made to the person the complainant is already in contact with over the matter being complained about. Whenever possible complaints will be dealt with by the relevant member of the editorial staff. If that person cannot deal with the complaint he or she will refer it to a section editor or the executive editor.
All complaints will be acknowledged within 10 working days. If possible a full response will be made within four weeks. If this is not possible an interim response will be given within 3 months. Further interim responses will be provided until the complaint is resolved.
Ethical approval of research
We welcome detailed explanations of how investigators and authors have considered and justified the ethical and moral basis of their work. If such detail does not easily fit into the manuscript please provide it in the covering letter or upload it as a supplemental file when submitting the article. We will also be pleased to see copies of explanatory information given to participants. Even if we do not include such detailed information in a final published version, we may make it available to peer reviewers and editorial committees. We already ask peer reviewers to consider and comment on the ethics of submitted work.
Ethics; when reporting studies on human indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html). Evidence for approval by a local Ethics Committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible and the details o anesthetics and analgesics used should be clearly stated. The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the ‘Materials and Methods’ section.
Online First publication
Most articles accepted for publication in RMM journal are published Online First within 3-4 weeks, often months ahead of publication in a printed journal issue. Online First articles are copy edited, typeset and approved by the author before being published as both typeset PDFs and searchable full text.
Peer reviewers
All articles received are subject to peer review. Double blind reviews are conducted and normally, three to five reviewers are invited for each article including highly qualified professional biostatisticians. The contributor could also provide names of three qualified reviewers who have had experience in the subject of the submitted manuscript, but who are not affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor.
Long-term Archiving
To preserve scholarly literature published in electronic form and to ensure that these materials remain available to future generations of scholars and researchers, Knowledge E content is archived in Portico, a not-for-profit organization with a mission and singular focus to provide a permanent archive of electronic scholarly content. Portico representative offices are located in New York, New Jersey, and Michigan.
Journal Content
- Year 2017
- Year 2016
- Year 2015
- Year 2014
- Year 2013
Contact Information
Knowledge E
Research in Molecular Medicine Editorial Office
Office 4401, Jumeirah Bay X2 Tower, Jumeirah Lakes Towers (JLT), 488239
Dubai, United Arab Emirates
Email: [email protected]
Tel.: +971 44 227 043
-------------------------------------------------
Mazandaran University of Medical Sciences
E-mail: [email protected] or [email protected]
Address: Sari Medical School, Mazandaran University of Medical Sciences,
Km 18 Khazar Abad Road, Khazar Sq, Sari, Iran.
P.O.Box: 48471-91971
Telefax: +98-111-33543614
http://rmm.mazums.ac.ir/
